Costamare (CMRE) Reaches $6.70 After 3.00% Down Move, Shorts at Ocular Therapeutix (OCUL) Lowered By 2.78%

May 30, 2017 - By Adrian Mccoy

Ocular Therapeutix Incorporated (NASDAQ:OCUL) had a decrease of 2.78% in short interest. OCUL’s SI was 6.34M shares in May as released by FINRA. Its down 2.78% from 6.52 million shares previously. With 659,700 avg volume, 10 days are for Ocular Therapeutix Incorporated (NASDAQ:OCUL)’s short sellers to cover OCUL’s short positions. The SI to Ocular Therapeutix Incorporated’s float is 27.9%. About 430,969 shares traded. Ocular Therapeutix Inc (NASDAQ:OCUL) has declined 9.50% since May 30, 2016 and is downtrending. It has underperformed by 26.20% the S&P500.

The stock of Costamare Inc (NYSE:CMRE) is a huge mover today! About 889,990 shares traded. Costamare Inc (NYSE:CMRE) has declined 13.83% since May 30, 2016 and is downtrending. It has underperformed by 30.53% the S&P500.The move comes after 9 months negative chart setup for the $713.67 million company. It was reported on May, 30 by Barchart.com. We have $6.50 PT which if reached, will make NYSE:CMRE worth $21.41M less.

Among 5 analysts covering Ocular Therapeutix (NASDAQ:OCUL), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ocular Therapeutix had 9 analyst reports since August 5, 2015 according to SRatingsIntel. As per Thursday, August 11, the company rating was initiated by JMP Securities. The company was maintained on Thursday, April 28 by Morgan Stanley. RBC Capital Markets maintained the shares of OCUL in report on Tuesday, November 15 with “Outperform” rating. Cantor Fitzgerald initiated it with “Overweight” rating and $35 target in Friday, February 10 report. As per Wednesday, August 5, the company rating was initiated by Nomura. Morgan Stanley upgraded the shares of OCUL in report on Thursday, February 18 to “Overweight” rating. Morgan Stanley downgraded Ocular Therapeutix Inc (NASDAQ:OCUL) on Friday, October 23 to “Equal-Weight” rating. As per Thursday, August 13, the company rating was initiated by Morgan Stanley. The stock has “Overweight” rating by Morgan Stanley on Tuesday, June 7.

Ocular Therapeutix, Inc. is a biopharmaceutical company. The company has market cap of $348.78 million. The Firm is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. It currently has negative earnings. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

Among 6 analysts covering Costamare (NYSE:CMRE), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Costamare had 11 analyst reports since December 18, 2015 according to SRatingsIntel. The rating was reinitiated by Barclays Capital with “Equal Weight” on Monday, January 11. The firm has “Overweight” rating given on Wednesday, February 1 by Morgan Stanley. Credit Suisse maintained Costamare Inc (NYSE:CMRE) rating on Friday, January 29. Credit Suisse has “Neutral” rating and $9 target. As per Monday, January 30, the company rating was downgraded by Credit Suisse. The stock has “Underweight” rating by JP Morgan on Friday, December 18. The stock of Costamare Inc (NYSE:CMRE) earned “Equal-Weight” rating by Morgan Stanley on Thursday, June 30. JP Morgan upgraded the stock to “Overweight” rating in Wednesday, October 5 report. The stock of Costamare Inc (NYSE:CMRE) earned “Neutral” rating by Credit Suisse on Monday, May 1. Stifel Nicolaus maintained Costamare Inc (NYSE:CMRE) rating on Thursday, May 25. Stifel Nicolaus has “Hold” rating and $700 target.